Here is a very attractive and brutally undervalued canadian company called Medicenna (MDNA.TO) which is listed since March thats why its also undicovered . This Cancer Play has a Phase 2 trial in recurrent Glioblastoma ongoing a $650 Million Market , they expect to complete enrollment by year end and to report results in early Q1 2018 . If the results are positive then they can file for accelerated approval in 2H 2018 and this makes this company with a terrible low valuation of only C$ 36 Million a super attractive opportunity which has 10 bagger potential easily on positive phase 2 results in Q1 2018 and FDA approval .Please do your own DD and realize the mega potential .GL
Medicenna Therapeutics (MDNA.TO)
Market Cap C$36 Million
Cash : C$ 20 Million << enough untill Q1 2019
Price : $1.50
Shares Out: 24.3 Million ( 15.5 Million shares held by Insider alone )
Medicenna Therapeutics (TSXV: MDNA) CEO: Our Drug Has Potential for Phase 2 Approval
smallcappower.com
New Presentation
s21.q4cdn.com
Fact Sheet
s21.q4cdn.com
Insider Ownership :
Aries Biologics, Inc. 5 500 000
Rosemina Merchant 5 050 000
Fahar Merchant 5 050 000
Elizabeth Williams 5 300
Chandrakant J. Panchal, PhD 1 000
Trevor P. Wong-Chor 714
 |
